Myriad Genetics Inc
XBER:MYD
Myriad Genetics Inc
Nestled at the crossroads of healthcare innovation and genetic science, Myriad Genetics Inc. has been a pioneering force in molecular diagnostics for over three decades. Founded in 1991 and headquartered in Salt Lake City, Utah, the company carved out its niche by focusing on predictive medicine—an area that seeks to forecast disease risk based on genetic predispositions. At the heart of Myriad's operations is its robust arsenal of genetic tests that identify individuals' risk for various conditions, including cancer, cardiovascular illnesses, and other hereditary disorders. This approach not only aids early intervention and personalized treatment plans but also empowers patients with crucial information about their genetic backgrounds.
Myriad's business model orbits around the research, development, and commercialization of these high-impact diagnostic tests. Revenue streams flow primarily from the sale of its flagship products, which include the BRACAnalysis CDx test for assessing breast and ovarian cancer risk and various other hereditary cancer tests that evaluate susceptibility to prostate and colorectal cancers. Further, Myriad advances its impact through collaborations with healthcare providers, folding clinical research findings into broader medical practice. In a world where healthcare is increasingly leaning towards precision medicine, Myriad Genetics stands as a testament to the value of science-led business strategies, sustaining its growth through a clear focus on marrying advanced genomic knowledge with accessible and actionable clinical applications.
Nestled at the crossroads of healthcare innovation and genetic science, Myriad Genetics Inc. has been a pioneering force in molecular diagnostics for over three decades. Founded in 1991 and headquartered in Salt Lake City, Utah, the company carved out its niche by focusing on predictive medicine—an area that seeks to forecast disease risk based on genetic predispositions. At the heart of Myriad's operations is its robust arsenal of genetic tests that identify individuals' risk for various conditions, including cancer, cardiovascular illnesses, and other hereditary disorders. This approach not only aids early intervention and personalized treatment plans but also empowers patients with crucial information about their genetic backgrounds.
Myriad's business model orbits around the research, development, and commercialization of these high-impact diagnostic tests. Revenue streams flow primarily from the sale of its flagship products, which include the BRACAnalysis CDx test for assessing breast and ovarian cancer risk and various other hereditary cancer tests that evaluate susceptibility to prostate and colorectal cancers. Further, Myriad advances its impact through collaborations with healthcare providers, folding clinical research findings into broader medical practice. In a world where healthcare is increasingly leaning towards precision medicine, Myriad Genetics stands as a testament to the value of science-led business strategies, sustaining its growth through a clear focus on marrying advanced genomic knowledge with accessible and actionable clinical applications.
Revenue Beat: Q4 revenue was $209.8 million, above the high end of guidance, with full-year 2025 revenue at $824.5 million.
Growth Drivers: MyRisk hereditary cancer test and Prolaris saw double-digit volume growth; GeneSight and oncology segments also posted solid gains.
Profitability: Q4 adjusted EBITDA reached $14.3 million and adjusted EPS was $0.04, both showing improvement.
2026 Guidance Reaffirmed: Full-year 2026 revenue is expected between $860–880 million with gross margins of 68–69% and no material MRD revenue contribution assumed.
Product Pipeline: Major product launches expected in 2026, including AI-enabled Prolaris, Precise MRD for multiple cancers, and FirstGene prenatal panel.
Prenatal Rebuild: Prenatal testing volumes declined due to earlier order management issues but are expected to recover starting in Q2 2026.
Cost Discipline: Operating expenses declined year-over-year, with investments redirected to sales and R&D ahead of new launches.
